Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 31, 2007
Business Overview: The Company operates through two primary segments: CooperVision (CVI), which markets contact lenses, and CooperSurgical (CSI), which manufactures medical devices and surgical instruments for gynecologists and obstetricians.
Key Financial Metrics
All figures in thousands, except per share data.
| Metric | Three Months Ended July 31, 2007 | Nine Months Ended July 31, 2007 |
|---|---|---|
| Net Sales | $251,862 | $696,817 |
| Gross Profit | $145,924 | $402,291 |
| Gross Margin | 58% | 58% |
| Operating Income | $23,658 | $49,951 |
| Net Income | $8,180 | $13,001 |
| Diluted EPS | $0.18 | $0.29 |
| Cash from Operating Activities | N/A (Quarterly) | $95,862 |
| Total Debt (Short + Long Term) | $861,286 | $861,286 |
| Cash and Cash Equivalents | $8,061 | $8,061 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12% ($26.1 million) for the quarter and 8% ($53.9 million) for the nine-month period compared to the prior year. Growth was driven by CooperVision (up 9% and 6% respectively) and CooperSurgical (up 26% and 24% respectively).
- Profitability Decline: Operating income decreased 27% to $23.7 million for the quarter and 45% to $50.0 million for the nine-month period. Net income dropped significantly, from $21.0 million to $8.2 million (quarter) and from $52.6 million to $13.0 million (nine months).
- Margin Compression: Gross margin declined from 61% to 58% (quarter) and 62% to 58% (nine months) due to manufacturing inefficiencies related to new silicone hydrogel product launches and integration costs.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 16% (quarter) and 15% (nine months). Research and development expenses increased 84% (quarter) and 17% (nine months), partly due to acquired in-process research and development charges.
- Debt Refinancing: In January 2007, the Company refinanced its credit facility, issuing $350 million in Senior Notes and establishing a $650 million Revolver. Total debt increased from $742.7 million (Oct 2006) to $861.3 million (July 2007).
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- Product Launches: The Company is rolling out silicone hydrogel lenses in the U.S. (commenced July 2007) and plans to launch a second silicone hydrogel spherical lens in mid-2008 and a toric version by end of 2008.
- Integration Costs: Integration of the Ocular Sciences acquisition is ongoing through mid-2008. Total restructuring costs are estimated at $45–$50 million, with approximately $36 million incurred through July 31, 2007.
- Capital Expenditures: Expected to be approximately $160 million for fiscal 2007, primarily for manufacturing expansion and distribution consolidation.
- Liquidity: Management believes cash on hand, operating cash flow, and credit facilities are sufficient to fund operations, dividends, and smaller acquisitions.
Risks and Contingencies
- Legal Proceedings:
- Securities Litigation: A consolidated class action lawsuit alleges misstatements regarding the Biomedics product line, Ocular integration, and accounting for acquired assets. The Company intends to vigorously defend.
- Patent Litigation: Ongoing disputes with Bausch & Lomb and CIBA Vision regarding contact lens patents (O2Optix and Biofinity lines). Trial dates are set for early 2008 and late 2008.
- Tax Litigation: A settlement with the IRS regarding Ocular Sciences tax returns for 1999–2001 was finalized at $3.5 million plus interest, which was paid in June 2007.
- Operational Risks: Risks include delays in regulatory approvals, manufacturing constraints for new silicone hydrogel materials, and potential impairment of goodwill (though no impairment was found in the Q3 2007 test).
Unusual Items
- Restructuring and Integration: Significant costs related to the Ocular integration plan, including distribution rationalization and plant shutdowns.
- Acquired In-Process R&D: Charges of $3.0 million (Q3) and $7.2 million (nine months) for acquired in-process research and development.
- Debt Issuance Costs: A $0.9 million write-off of debt issuance costs related to the extinguishment of the prior term loan.
Investor Verification Checklist
- Integration Progress: Verify the timeline and cost realization of the Ocular Sciences integration plan, specifically the $45–$50 million total cost estimate.
- Silicone Hydrogel Ramp-up: Monitor the success of the U.S. launch of silicone hydrogel lenses and the associated manufacturing efficiency improvements to restore gross margins.
- Legal Exposure: Track the status of the securities class action and patent litigation with CIBA Vision and Bausch & Lomb, as outcomes could materially impact financial results.
- Debt Covenants: Confirm continued compliance with the Interest Coverage Ratio (currently 6.15:1) and Total Leverage Ratio (currently 3.47:1) under the new credit facility.
- Effective Tax Rate: Monitor the effective tax rate, which increased to 33.3% for the nine-month period due to geographic income mix changes and integration expenses in lower-tax jurisdictions.